首页> 外文期刊>Stem cells international >Assessment of Safety and Functional Efficacy of Stem Cell-Based Therapeutic Approaches Using Retinal Degenerative Animal Models
【24h】

Assessment of Safety and Functional Efficacy of Stem Cell-Based Therapeutic Approaches Using Retinal Degenerative Animal Models

机译:使用视网膜退行性动物模型评估干细胞的治疗方法的安全性和功能性疗效

获取原文
获取原文并翻译 | 示例
       

摘要

Dysfunction and death of retinal pigment epithelium (RPE) and or photoreceptors can lead to irreversible vision loss. The eye represents an ideal microenvironment for stem cell-based therapy. It is considered an "immune privileged" site, and the number of cells needed for therapy is relatively low for the area of focused vision (macula). Further, surgical placement of stem cell-derived grafts (RPE, retinal progenitors, and photoreceptor precursors) into the vitreous cavity or subretinal space has been well established. For preclinical tests, assessments of stem cell-derived graft survival and functionality are conducted in animal models by various noninvasive approaches and imaging modalities. In vivo experiments conducted in animal models based on replacing photoreceptors and/or RPE cells have shown survival and functionality of the transplanted cells, rescue of the host retina, and improvement of visual function. Based on the positive results obtained from these animal experiments, human clinical trials are being initiated. Despite such progress in stem cell research, ethical, regulatory, safety, and technical difficulties still remain a challenge for the transformation of this technique into a standard clinical approach. In this review, the current status of preclinical safety and efficacy studies for retinal cell replacement therapies conducted in animal models will be discussed.
机译:视网膜颜料上皮(RPE)和或光感受器的功能障碍和死亡可导致不可逆的视力丧失。眼睛代表了基于干细胞疗法的理想微环境。它被认为是一个“免疫特权”的部位,治疗所需的细胞数量对于聚焦视觉(Macula)的面积相对较低。此外,已经很好地建立了干细胞 - 衍生的移植物(RPE,视网膜,视网膜祖细胞和感光剂前体)的外科静电腔体或体积腔空间。对于临床前测试,通过各种非侵入性方法和成像方式在动物模型中进行干细胞衍生的移植物存活和功能的评估。在基于替代光感受器和/或RPE细胞的动物模型中进行的体内实验表明了移植细胞的存活率和功能,宿主视网膜的拯救以及可视功能的改善。基于从这些动物实验获得的阳性结果,正在启动人类临床试验。尽管干细胞研究中的进展,但伦理,监管,安全和技术困难仍然是将该技术转化为标准临床方法的挑战。在本文中,将讨论在动物模型中进行的视网膜细胞替代疗法的临床前安全性和功效研究的当前状态。

著录项

  • 来源
    《Stem cells international》 |2017年第4期|共19页
  • 作者单位

    Univ Southern Calif Dept Ophthalmol USC Roski Eye Inst Los Angeles CA 90089 USA;

    Univ Calif Irvine Stem Cell Res Ctr Irvine CA USA;

    Univ Southern Calif Dept Ophthalmol USC Roski Eye Inst Los Angeles CA 90089 USA;

    Univ Southern Calif Dept Ophthalmol USC Roski Eye Inst Los Angeles CA 90089 USA;

    Univ Southern Calif Dept Ophthalmol USC Roski Eye Inst Los Angeles CA 90089 USA;

    Univ Calif Santa Barbara Ctr Stem Cell Biol &

    Engn Santa Barbara CA 93106 USA;

    Univ Southern Calif Dept Ophthalmol USC Roski Eye Inst Los Angeles CA 90089 USA;

    Univ Southern Calif Dept Ophthalmol USC Roski Eye Inst Los Angeles CA 90089 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 生物工程学(生物技术);
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号